StockData

Arcutis Biotherapeutics vs Tarsus Pharmaceuticals

ARQT and TARS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARQT and TARS compare

Arcutis Biotherapeutics and Tarsus Pharmaceuticals are about the same size, with market caps of $3.4B and $3.5B.

Tarsus Pharmaceuticals grew revenue faster over the last twelve months (105% versus 76.1% for Arcutis Biotherapeutics).

Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 6.1% compared with −7.7% at Tarsus Pharmaceuticals.

Arcutis Biotherapeutics scores higher on the StockData Score (11 against 10 for Tarsus Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARQTTARS
Size and price
Market cap$3.4B$3.5B
Share price$27.15$78.68
Change, 1 year18.8%8.5%
Change, 5 years62.9%215%
Beta (5Y)1.170.84
Employees354370
StockData Score
Total score11 (better)10
Valuation score00
Growth score4 (better)3
Performance score4 (better)3
Health score34 (better)
Dividend score00
Valuation
P/E123×–
P/S7.4×5.7× (better)
P/B15.5×10.0× (better)
EV/EBITDA95.8×–
P/FCF87.2×61.7× (better)
FCF yield1.1%1.6% (better)
Fair value$5.46$75.97
Margin of safety−397%−3.6% (better)
Growth
Revenue growth (TTM)76.1%105% (better)
Profitability
Gross margin91.1%–
Operating margin7.4% (better)−8.0%
Net margin6.1% (better)−7.7%
FCF margin8.4%9.2% (better)
Return on equity15.9% (better)−13.7%
Return on invested capital36.9%–
Financial health
Debt / equity0.490.21 (better)
Net debt / EBITDA−3.79–
Interest coverage2.5× (better)−5.5×
Current ratio2.923.20 (better)
Altman Z-score6.338.29 (better)
Piotroski F-score44
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions105%110%
Held by insiders9.3%3.1%
Insider net buying, 12 months−$11.1M (better)−$20.0M
Short interest, % of float15.9%14.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.